Equity Profile

GMED

Globus Medical, Inc.

Health CareHealth Care Equipment$10.9B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, focusing on developing innovative spinal and orthopedic implants....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $1.12.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GMED Q2-2026 Earnings Preview

Context

Company Snapshot

Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, focusing on developing innovative spinal and orthopedic implants. With a market cap of $11 billion, its products aim to improve patient outcomes and enhance surgical efficiency, making it a significant player in the growing health care market.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.40%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Globus Medical reported an EPS of $1.12, exceeding expectations by 22%. Despite the positive earnings surprise, the stock fell by 4.65% the following day.

Management Promises & Guidance

Focus on expanding product lines in spinal surgery.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, analysts expect a solid performance from Globus Medical, given its history of exceeding EPS estimates. However, concerns about revenue growth and market competition may temper enthusiasm.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

If the company fails to meet revenue expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor concerns.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.12.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and increase sales, crucial for long-term success.

Gross Margin

Not available.

Gross margin indicates how efficiently the company produces its products and can impact overall profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

Given the company's strong history of beating EPS estimates, this will be a critical measure of ongoing performance and investor confidence.

What is the outlook for revenue growth in the upcoming quarters?

Investors will be keen to understand if the company can maintain its growth trajectory, especially in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth in emerging markets, which could significantly boost overall sales.

Supporting Evidence

The company's recent product launches have received positive feedback from surgeons, indicating strong demand.

Options pricing suggests a larger move than historical averages, indicating potential for significant surprises.

Insider buying activity may suggest confidence in the company's future performance.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to sustain its earnings momentum while addressing market challenges.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.00 would signal potential issues in profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±16.79%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±16.8% while GMED has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.1%

Calls (2K)P/C Ratio: 4.19Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GMED beats expectations, history suggests the stock could rise by around 1.66% on the first day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting cautious investor sentiment.

Miss

If the company misses expectations, history suggests a potential decline of about 1.33%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on sales.
2Insights into market expansion strategies, particularly in emerging markets.
3Management's commentary on operational efficiencies and cost management.
4Details on customer feedback and engagement initiatives.
5Guidance on future earnings and revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, focusing on developing innovative spinal and orthopedic implants....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $1.12.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GMED Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.40%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Globus Medical reported an EPS of $1.12, exceeding expectations by 22%. Despite the positive earnings surprise, the stock fell by 4.65% the following day.

Management Promises & Guidance

Focus on expanding product lines in spinal surgery.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, analysts expect a solid performance from Globus Medical, given its history of exceeding EPS estimates. However, concerns about revenue growth and market competition may temper enthusiasm.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

If the company fails to meet revenue expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor concerns.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.12.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and increase sales, crucial for long-term success.

Gross Margin

Not available.

Gross margin indicates how efficiently the company produces its products and can impact overall profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

Given the company's strong history of beating EPS estimates, this will be a critical measure of ongoing performance and investor confidence.

What is the outlook for revenue growth in the upcoming quarters?

Investors will be keen to understand if the company can maintain its growth trajectory, especially in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth in emerging markets, which could significantly boost overall sales.

Supporting Evidence

The company's recent product launches have received positive feedback from surgeons, indicating strong demand.

Options pricing suggests a larger move than historical averages, indicating potential for significant surprises.

Insider buying activity may suggest confidence in the company's future performance.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to sustain its earnings momentum while addressing market challenges.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.00 would signal potential issues in profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±16.79%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±16.8% while GMED has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.1%

Calls (2K)P/C Ratio: 4.19Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GMED beats expectations, history suggests the stock could rise by around 1.66% on the first day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting cautious investor sentiment.

Miss

If the company misses expectations, history suggests a potential decline of about 1.33%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on sales.
2Insights into market expansion strategies, particularly in emerging markets.
3Management's commentary on operational efficiencies and cost management.
4Details on customer feedback and engagement initiatives.
5Guidance on future earnings and revenue expectations.